[Study on the correlation between HIV drug resistance and CD4+ T-lymphocyte of AIDS patients under antiretroviral treatment in Henan province].
OBJECTIVE
To study the correlation between genotype drug resistance and CD(4)(+) T-lymphocyte of AIDS patients who received antiretroviral treatment in Henan province.


METHODS
Several indicators were studied through questionnaires and whole blood was collected to analyze CD4+ T-lymphocyte as well as the virus load. In-House technique was used to detect the genotype drug resistance.


RESULTS
32.21% and 29.17% of the patients were identified as genotype drug resistant to AIDS when used first and second generation medicine schemes but the improvement (P = 0.7538) of disease process was not influenced much. However, if the genotype drug resistance of patients with HAART last longer than two years (33.20%) or patients with HAART less than one year (18.97%), a greater impact on the improvement was noticed. Age (OR = 0.68) and the interval on distribution of medicines (OR = 1.93) had a great impact on the improvement with the genotype drug resistance through logistic regression analysis. Medicine scheme (OR = 0.51), genotype drug resistance (OR = 3.20) and the rate of regular dose in a month (OR = 0.51) all had a great impact on the improvement to CD4+ T-lymphocyte by logistic regression analysis.


CONCLUSIONS
Part of HIV/AIDS patients showed resistant to genotype drugs in Henan province, suggesting that we must reinforce the surveillance on HAART and program on drug administration to the patients, in order to increase the number of CD4+ T-lymphocyte so as to avoid the development of drug resistance.
Zhu
Xin-peng
XP
Henan Provincial Center for Disease Control and Prevention, Zhengzhou 450016, China.
Li
Hong
H
Liu
Hong-wei
HW
Yuan
Yuan
Y
Liu
Chun-hua
CH
Zhu
Qian
Q
Cui
Wei-guo
WG
Wang
Zhe
Z
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000276:immunology* / Q000821:virology*; D000293:Adolescent; D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes; D002648:Child; D002675:Child, Preschool; D002681:China; D024882:Drug Resistance, Viral / Q000235:genetics*; D005260:Female; D005838:Genotype; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D055815:Young Adult
D019380:Anti-HIV Agents